Chimeric antigen receptor (CAR) T cells, an immunotherapy that has been successful in treating blood cancers, has had limited efficacy in solid tumors including in pancreatic cancer. Greg Allen, MD, […]
First RAS inhibitor approved by the FDA
Today daraxonrasib, an oral RAS(ON) multi-selective inhibitor from Revolution Medicines, was approved by the FDA for use by patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) or for patients […]
Increasing Survival Through Early Detection
At the 20th Annual Hirshberg Symposium, Dr. Margaret Tempero, the Director of the Cancer Early Detection and Interception Initiative and the leader of the Pancreas Center Program at the UCSF […]
New Vaccine to Prevent Pancreatic Cancer in High-Risk Patients
Using an “off-the-shelf” vaccine, researchers from Johns Hopkins Kimmel School of Medicine and Skip Viragh Center for Pancreatic Cancer have demonstrated, for the first time, the ability to generate an […]
Targeting RAS in Pancreatic Cancer: A New Reality
RAS Inhibition: A New Era for Pancreatic Cancer Treatment The RAS family of proteins have long been an area of study for understanding and targeting in pancreatic cancer. The exciting […]
Hope on the Horizon, a 2026 Progress Report on Pancreatic Cancer
At the 20th Annual Symposium on Pancreatic Cancer, Dr. Timothy Donahue, Director of the UCLA Agi Hirshberg Center for Pancreatic Diseases, presented the Pancreatic Cancer Progress Report for 2026. Dr. […]